HLN: Multiplikator P/S Haleon Group
High loyalty to established brands guarantees a steady customer inflow, as confirmed by the P/S chart for Haleon plc. The value of 2.70 indicates the level of this metric, correlating business value with revenue. Haleon plc dominates the OTC segment, leveraging its global leadership in consumer healthcare and the brand recognition of Sensodyne and Theraflu.
Rincian metrik lan analitis perusahaan Haleon Group (HLN)
- rega saham lan konsensus proyeksi valuasi:
- informasi kapitalisasi pasar:
- data ekuitas miturut neraca:
- indikator beban kredit lan likuiditas emiten:
- rincian asil keuangan lan kelipatan valuasi:
HLN - Bathi resik|Bathi mangsa ngarep Haleon plc|HLN - Pangali P/E|Pangali mangsa ngarep rega marang bathi Haleon PLC|HLN - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Haleon Group|HLN - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajrone 12 wulan pungkasan Haleon|HLN - Bathi saben saham sajrone rolas wulan pungkasan|Dinamika bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan haleon.com|HLN - Wutah bathi ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Haleon plc
- rincian pendapatan lan dodolan emiten:
Ringkesan analitik perusahaan:haleon.com, HLN
The P/S ratio compares the market value of Haleon plc (HLN) to its sales volume, making it possible to determine the extent of overpayment for the business relative to the generated cash flow. By analyzing the price-to-sales ratio, an investor can timely recognize price overheating, which is critical for capital preservation when investing in a global consumer healthcare leader with high consumer loyalty.
Pesaing Haleon plc
KVUE (kenvue.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S VRNA (Verona Pharma)|Multiplikator P/S Jyong Biotech Limited MENS|LGND - Rasio rega marang pendapatan|AMRX: Rasio rega marang pendapatan|PRGO: Multiplikator P/S|Rega marang dodolan alvotech.com (ALVO)|Rasio rega marang pendapatan Liquidia|Rega marang dodolan Galapagos N.V. GLPG|Rasio rega marang pendapatan ANI Pharma (ANIP)|Afrezza - Rasio kapitalisasi marang pendapatan|Amphastar Pharmaceuticals - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan PCRX|SPRY - Rasio rega marang pendapatan|Rasio rega marang dodolan TBPH|Aquestive Pharma (AQST) - Rasio rega marang pendapatan|SCPH (scPharmaceuticals) - Rasio rega marang pendapatan|TECX (Tectonic Therapeutic Inc.) - Multiplikator P/S|Kapitalisasi marang pendapatan tonixpharma.com (TNXP)|Multiplikator P/S SXTC|EPRX (eupraxiapharma.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan BioHarvest BHST|Invizyne - Rasio rega marang pendapatan|ORMP - Rasio rega marang pendapatan|ENTX (Entera Bio Ltd.) - Rasio kapitalisasi marang pendapatan|MindWalk Holdings Inc. (HYFT) - Rasio rega marang pendapatan|Rasio rega marang dodolan ABVC (ABVC BioPharma Inc.)|CPIX (Cumberland Pharma) - Multiplikator P/S|QNTM: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S FGEN|Multiplikator P/S telomirpharma.com (TELO)|Rasio rega marang pendapatan Rani Therapeutics Holdings, Inc. RANI|Rasio kapitalisasi pasar marang pendapatan SNYR|RLYB - Rasio rega marang pendapatan|Lexaria Bioscience (LEXX) - Kapitalisasi marang pendapatan|PULM: Multiplikator P/S|Pheton Holdings (PTHL) - Multiplikator P/S|Kapitalisasi marang pendapatan APM|LYRA: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Impact BioMedical (IBO)|TNFA - Rega marang dodolan|cbdMD - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan PRFX (painreform.com)|Auris Medical - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan LIPO (Lipella Pharmaceuticals Inc)|OPTN: Multiplikator P/S|Rega marang dodolan Pieris Pharma (PIRS)|Rasio rega marang pendapatan Procaps Group S.A.|PTPI: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S QLI|SLRN (Acelyrin Inc.) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S TFFP (TFF Pharma)
